Synergistic Combination Therapies for Progeroid Diseases and Conditions

This inventive concept integrates combination therapies for progeroid diseases and conditions with cutting-edge technologies like AI, IoT, and blockchain to create a more powerful system for personalized treatment, remote monitoring, and optimized treatment outcomes.

The original patent disclosed combination therapies for progeroid diseases and conditions, cellular aging, and atherosclerosis. However, these therapies had limitations in terms of patient monitoring, data analysis, and treatment optimization. The new inventive concept addresses these limitations by incorporating synergistic combinations of technologies to create a more comprehensive and effective system.

The inventive concept comprises a combination therapy module, blockchain-based tracking module, artificial intelligence algorithm, machine learning module, IoT-enabled sensor, and cloud-based server. The combination therapy module administers a therapeutically effective dose of a farnesyltransferase inhibitor and an mTOR inhibitor. The blockchain-based tracking module monitors patient treatment outcomes, ensuring transparency and security. The artificial intelligence algorithm optimizes dosages based on patient data, while the machine learning module analyzes genomic data to identify susceptible patients. The IoT-enabled sensor collects patient data, which is analyzed by the artificial intelligence algorithm to predict treatment outcomes. The cloud-based server provides personalized treatment recommendations.

The new inventive concept is novel and non-obvious compared to the original patent because it integrates distinct technologies to create a synergistic system that provides personalized treatment, remote monitoring, and optimized treatment outcomes. The use of blockchain, AI, IoT, and machine learning modules in combination with the original combination therapies is an inventive step that addresses the limitations of the original patent.

Alternative embodiments of the inventive concept could include the use of different AI algorithms, machine learning models, or IoT-enabled devices. Variations could include integrating additional technologies like nanotechnology or gene editing to further enhance the system's capabilities.

The inventive concept has significant commercial potential in the pharmaceutical and healthcare industries, particularly in the areas of personalized medicine, remote patient monitoring, and precision therapy. The target market includes pharmaceutical companies, hospitals, and research institutions focused on progeroid diseases and conditions.